From clinical trials to clinical practice: An overview of Certican® (everolimus) in heart transplantation

Journal of Heart and Lung Transplantation

Volumn 24, Issue 4 SUPPL., 2005, Pages

  Valantine, Hannah ^a,c   Zuckermann, Andreas ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRAFT REJECTION; ARTERY INTIMA PROLIFERATION; BACTERIAL INFECTION; BIOPSY; CARDIAC ALLOGRAFT VASCULOPATHY; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RATE; INHIBITION KINETICS; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; POPULATION; PRIORITY JOURNAL; RECIPIENT; REVIEW; SMOOTH MUSCLE FIBER; STANDARD; SURGICAL PATIENT; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 15044343276     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2005.01.013     Document Type: Article

References (27)

1. D.O. Taylor, L.B. Edwards, P.J. Mohacsi The registry of the International Society for Heart and Lung Transplantation twentieth official adult heart transplant report--2003 J Heart Lung Transplant 22 2003 616 624
2. L.D. Sharples, C.H. Jackson, J. Parameshwar, J.M. Wallwork, S.R. Large Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy Transplantation 76 2003 679 682
3. H.A. Valantine The role of viruses in cardiac allograft vasculopathy Am J Transplant 4 2004 169 177
4. V. Klauss, A. Konig, C. Spes Cyclosporine versus tacrolimus (FK506) for prevention of cardiac allograft vasculopathy Am J Cardiol 85 2000 266 269
5. J. Kobashigawa, L. Miller, D. Renlund A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients Transplantation 66 1998 507 515
6. Kobashigawa J. Further analysis of the intravascular ultrasound (IVUS) data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients. Data presented at the 24th annual meeting of the International Society for Heart and Lung Transplantation, San Francisco, CA, April 2004.
7. B. Nashan The role of Certican® (everolimus, RAD) in the many pathways of chronic rejection Transplant Proc 33 2001 3215 3220
8. W. Schuler, R. Sedrani, S. Cottens SDZ RAD, a new rapamycin derivative pharmacological properties in vitro and in vivo Transplantation 64 1997 36 42
9. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients N Engl J Med 349 2003 847 858
10. T. Nishimura, J.L. Faul, G.L. Berry 40-o-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats Am J Respir Crit Care Med 163 2001 498 502
11. A. Farb, M. John, E. Acampado Oral everolimus inhibits in-stent neointimal growth Circulation 106 2002 2379 2384
12. O.J. Cole, M. Shehata, K.M. Rigg Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model Transplant Proc 30 1998 2200 2203
13. H.J. Schuurman, C. Pally, G. Weckbecker, W. Schuler, C. Bruns SDZ RAD inhibits cold ischemia-induced vascular remodeling Transplant Proc 31 1999 1024 1025
14. Y. Matsumoto, A. Hof, Y. Baumlin Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid artery allografts in apolipoprotein E-deficient mice Transplantation 76 2003 1166 1170
15. E. Grube, S. Sonoda, F. Ikeno Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer Circulation 109 2004 2168 2171
16. A. Haverich, E.M. Tuzcu, M. Viganò Everolimus in de novo cardiac transplant recipients 24-month follow-up (abstract) J Heart Lung Transplant 22 Suppl 1S 2003 S140
17. H. Valentine, H. Eisen, R. Dorent 12-Month results of a multicenter study comparing efficacy and safety of everolimus to azathioprine in de novo cardiac transplant recipients (abstract) Am J Transplant 2 suppl 3 2002 247
18. W. Hauck, D. Delgado, S. Perrone Everolimus reduces cardiac allograft vasculopathy in de novo heart transplant recipients 24 month follow-up (abstract) Can J Cardiol 19 suppl A 2003 90A
19. D. Mancini, M. Viganò, L.A. Pulpon 24-Month results of a multicenter study of Certican© for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients Am J Transplant 3 suppl 5 2003 550
20. S.R. Kapadia, K.M. Ziada, P.L. L'Allier Intravascular ultrasound imaging after cardiac transplantation advantage of multi-vessel imaging J Heart Lung Transplant 19 2000 167 172
21. P.R. Rickenbacher, F.J. Pinto, N.P. Lewis Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation Circulation 92 1995 3445 3452
22. Kobashigawa JA, Tobis JA, Starling RC, et al. Multicenter intravascular ultrasound (IVUS) validation study among heart transplant recipients: outcomes after 5 years. J Am Coll Cardiol (in press).
23. J. Jiminez, S.R. Kapadia, M.H. Yamani Cellular rejection and rate of progression of transplant vasculopathy a 3-year serial intravascular ultrasound study J Heart Lung Transplant 20 2001 393 398
24. Data on file, Novartis Pharma AG, Basel, Switzerland.
25. J.M. Kovarik, B. Kaplan, H. Tedesco Silva Exposure-response relationships for everolimus in de novo kidney transplantation defining a therapeutic range Transplantation 73 2002 920 925
26. R.C. Starling, J.M. Hare, P. Hauptman Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling Am J Transplantation 4 2004 2126 2131
27. A. Keogh, M. Richardson, P. Ruygrok Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years Circulation 110 2004 10 16